Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768482 · ClinicalTrials.gov registry record · Phase 3
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT00768482: Clinical Trial Phase 3 study, sponsored by Titan Pharmaceuticals.
NCT00768482 is a Phase 3 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 9 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00768482, a Phase 3 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
Interventions
- DRUG Probuphine (buprenorphine implant)
- DRUG Sublingual Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Why NCT00768482 stopped before completion
NCT00768482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Probuphine (buprenorphine implant) is the first listed.
NCT00768482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00768482 about?
NCT00768482 is a clinical study titled "A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence". This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
What is the current status of trial NCT00768482?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00768482?
The interventions under investigation include: Probuphine (buprenorphine implant) (DRUG), Sublingual Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00768482?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00768482's enrollment target sits among peer trials
9 1992nd of 2000 higher than 8 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia